Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

  title={Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.},
  author={Gabriel {\'E}tienne and Joelle Guilhot and Delphine R{\'e}a and Françoise Rigal‐Huguet and Franck Emmanuel Nicolini and Aude Charbonnier and Agn{\'e}s Guerci-Bresler and Laurence Legros and B. Varet and Martine Gardembas and Viviane Dubruille and Micheline Tulliez and Marie Pierre Noel and Jean-Christophe Ianotto and Bruno Villemagne and Martin Carr{\'e} and François Guilhot and Philippe Rousselot and François Xavier Mahon},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={35 3},
  • G. ÉtienneJ. Guilhot F. Mahon
  • Published 20 January 2017
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. [] Key Method Patients and Methods IM was prospectively discontinued in 100 patients with CML with UMRD sustained for at least 2 years.

Figures and Tables from this paper

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

Serial high sensitivity testing provides a new and unexpected finding of gradually reducing CML cells in patients in long-term TFR in patients with undetectable BCR-ABL1 mRNA.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

The duration of TKI and residual leukemic cell load as determined by ddPCR are key factors for predicting successful treatment-free remission for patients with de novo chronic phase CML.

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

The results demonstrate that TKI treatment discontinuation is feasible in real-life clinical practice and a significant increase in Hb and cholesterol levels was observed after imatinib withdrawal.

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Durations of imatinib treatment and deep molecular response as well as BCR::ABl1/ABL1 levels at cessation of tyrosine kinase inhibitor treatment, as quantified by reverse transcriptase droplet digital polymerase chain reaction, are involved in molecular recurrence occurring up to 24 months but not beyond.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study

The findings suggest that CML patients who meet all the eligibility criteria that have commonly been used in the TFR trials are able to discontinue imatinib use safely, and TFR may be valuable as a new goal for CML treatment in Japan.

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.

The New ELN Recommendations for Treating CML

Generic imatinib is the current most cost-effective first-line therapy in the chronic phase and a change of treatment is recommended when intolerance cannot be ameliorated or molecular milestones are not reached.

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

These results demonstrate that under proper conditions, treatment discontinuation is feasible outside of clinical trial setting and are associated with very low risk of loss of MR4.5.

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission.

These late events represent 14% of all MRec and occur in patients with fluctuating MRD measurements, and a long-term molecular follow-up therefore remains mandatory for CML patients in TFR.



Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

It is hypothesized that relapses observed within 6 months reflect the kinetics of undetectable dividing chronic myelogenous leukemia (CML) cells, which may be eradicated or controlled in long-term nonrelapsing patients, as described in the study.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

In conclusion, discontinuation of first-line or subsequent 2G-TKI yields promising TFR rates without safety concerns and a landmark analysis demonstrated that loss of MR4.5 3 months after stopping TKI was predictive of failure to maintain MMR later on.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR, and should be a criterion for resuming therapy.

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib

The data strongly suggest that immunological control contributes to sustained suppression of residual leukemia cell expansion and that IM can be safely discontinued in patients with post‐transplant relapse.

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC), and the toxicity profile was unchanged.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

The results confirm the safety and efficacy of a trial of imatinib withdrawal in stable UMRD with frequent, sensitive molecular monitoring and early rescue of molecular relapse, and show persistence of the original CML clone in all patients with stable U MRD, even several years after imatinIB withdrawal.

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

It is confirmed that Imatinib can be safely and prospectively discontinued in pts with DMR of at least 2 years duration in patients only treated with imatinib and that all patients were sensitive to a TKI re-challenge.

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Positivity (defined as ≥ 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before Imatinib discontinuation were associated with a higher probability of sustained major molecular response and minimal residual leukemia measured by digital polymerases chain reaction had a trend for a higher molecular relapse.

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP, and few deaths in any arm were associated with CVEs, infections or pulmonary diseases.